14th Dec 2009 07:00
14 December 2009
Vernalis announces clinical update on partnered compounds AUY922 and HSP990
Vernalis plc (LSE: VER) today announces that at its 9 December 2009 Oncology and Pipeline Update, Novartis provided an update on the clinical status of two Hsp90 inhibitors (AUY922 and HSP990), which are partnered with Vernalis.
In a presentation, Novartis indicated that it expects that several compounds may reach proof of concept in 2010, including AUY922, and that HSP990 is in Phase I dose escalation studies.
More information can be found on Novartis' website (www.novartis.com).
-- ends --
Enquiries:
|
Vernalis Contacts |
|
|
Ian Garland, Chief Executive Officer |
+44 (0) 118 989 9360 |
|
David Mackney, Chief Financial Officer |
|
|
Brunswick Group |
|
|
Jon Coles |
+44 (0) 20 7404 5959 |
|
Justine McIlroy |
Notes to Editors
About Vernalis
Vernalis is a development stage pharmaceutical company with significant expertise both in de novo fragment and structure-based drug discovery and pre-clinical and clinical development. The Group has seven product candidates in clinical development (three of which are partnered), two programmes in pre-clinical, as well as other competitive research programmes. Our technologies, capabilities and products are endorsed by collaborations with leading, global pharmaceutical companies including GSK, Biogen Idec, Novartis, Servier, Chiesi, Menarini, and Endo.
|
Product |
Indication |
Pre-Clinical |
Phase I |
Phase II |
Phase III |
Marketing Rights |
|
Priority Programmes |
||||||
|
V3381 |
Neuropathic Pain |
X |
Worldwide |
|||
|
V2006 |
Parkinson's Disease |
X |
Biogen Idec |
|||
|
V85546 |
Inflammatory Disease |
X |
Worldwide |
|||
|
NVP-AUY922 |
Cancer |
X |
Novartis |
|||
|
NVP-HSP990 |
Cancer |
X |
Novartis |
|||
|
V3381 CC |
Chronic Cough |
X |
Worldwide |
|||
|
V158866 |
Pain |
X |
Worldwide |
|||
|
V158411 (Chk1) |
Cancer |
X |
Worldwide |
|||
|
Progress through partnering |
||||||
|
V1512 |
Parkinson's Disease |
X |
Worldwide (excl. Italy) |
|||
|
V10153 |
Ischaemic Stroke |
X |
Worldwide |
|||
For further information about Vernalis, please visit www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of Frova® and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
Related Shares:
Vernalis PLC